ADHD is no longer peripheral to Australian general practice. Rising patient demand, prolonged specialist wait times, and growing public awareness mean GPs are now central to ongoing ADHD care. For pharmaceutical companies, this creates a clear opportunity, but also exposes the limits of traditional engagement models.











